SubsidieMeestersThe first wide range flow sensor to unlock microfluidic cell analyses for preclinical studies
The project aims to develop the GALILEO flow sensor to enhance microfluidic cell assays, improving therapeutic success rates and enabling earlier detection and treatment in drug development.
Projectdetails
Introduction
There is a critical need to improve the diagnosis, drug discovery, and development pipeline to increase the success rate of new therapeutics (as low as 3.4% for cancer drugs) and provide earlier detection and treatment. Microfluidic cell-based assays and analyses are one of the most promising strategies, supported by direct feedback from industry and regulatory agencies.
Technology Overview
Integrated microscale fluidics adds an extra dimension to in vitro cell cultures and is an enabling technology for single-cell analyses and nanotherapies. However, the main limitations with these platforms expressed by our clients from academia and industry are:
- Inability to measure and control flow rate over a wide enough range (100-times too narrow).
- Imprecision in measurements.
- Failure to detect sensor drift that leads to experimental error.
Our GALILEO flow sensor innovation demonstrates the technical ability to address these pressing requirements for microfluidic cell assays and analyses. This proposal will advance the proof of concept to a viable demonstrator of the technology for beta testing.
Market Opportunity
The timing is ideal for our solution: expressed end-user demand is high, and legislative bodies have voted to reduce animal testing by 2035. GALILEO has a strong competitive advantage in the microfluidic flow sensor market with a Serviceable Available Market (SAM) of 535 million EUR/year, increasing with the growth of next-generation sequencing and genomic medicine.
Company Background
Elvesys is an entrepreneur-led microfluidics instrument company with demonstrated success in the development and commercialization of 15 instruments for microfluidic flow control, and the generation of 10 growing spin-offs in the last 11 years.
Innovation Approach
Our end-user feedback and iterative testing approach to innovation puts us in a position of strength to execute an optimal product-market fit, targeting market creation. We have the proven technical expertise to deliver on GALILEO performance, and the market contact breadth to disseminate, exploit, and communicate the technology to all stakeholders.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 1.667.500 |
| Totale projectbegroting | € 1.667.500 |
Tijdlijn
| Startdatum | 1-5-2023 |
| Einddatum | 30-4-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ELVESYSpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
LUCERO BIO: Smart Optofluidic Isolation of Spheroids for Early-Stage Drug DiscoveryLucero aims to enhance drug screening by developing a scalable 3D cell-handling platform using microfluidics and AI, enabling personalized medicine and improving treatment efficacy in pharmaceuticals. | EIC Transition | € 1.298.712 | 2023 | Details |
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samplesThe NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs. | EIC Transition | € 2.499.999 | 2025 | Details |
Fully automated cell-free DNA extraction and quantification - liquid biopsies safely from Patient to LabBiopSense aims to develop and validate a fully automated disposable cartridge for cfDNA extraction from blood, enhancing reliability and transport ease for cancer diagnostics and prenatal screening. | EIC Transition | € 2.500.000 | 2022 | Details |
LUCERO BIO: Smart Optofluidic Isolation of Spheroids for Early-Stage Drug Discovery
Lucero aims to enhance drug screening by developing a scalable 3D cell-handling platform using microfluidics and AI, enabling personalized medicine and improving treatment efficacy in pharmaceuticals.
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samples
The NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs.
Fully automated cell-free DNA extraction and quantification - liquid biopsies safely from Patient to Lab
BiopSense aims to develop and validate a fully automated disposable cartridge for cfDNA extraction from blood, enhancing reliability and transport ease for cancer diagnostics and prenatal screening.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
SmartIVHet project onderzoekt de haalbaarheid van een bio-geïnspireerd inline infuusmonitoringsysteem om de veiligheid van IV-infusen te verbeteren door nauwkeurige flowmeting en commerciële strategieën te evalueren. | Mkb-innovati... | € 19.983 | 2022 | Details |
Fast and simple biomarker detection by computational microscopyWe developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics. | ERC Proof of... | € 150.000 | 2024 | Details |
Development and validation of the first digital, clinical grade flow cytometry platform for enhanced diagnosis accuracy and sustainability in immunology and hemato oncologyMETAflow aims to revolutionize clinical flow cytometry by providing an automated, user-friendly platform for comprehensive data analysis, enhancing usability and robustness in diagnostics. | EIC Accelerator | € 2.499.579 | 2023 | Details |
Deep Label-Free Cell Imaging of Liquid Biopsies for Cancer MonitoringDevelop and commercialize a label-free interferometric phase microscopy device with AI for cost-effective cancer diagnosis and monitoring via liquid biopsies. | ERC Proof of... | € 150.000 | 2023 | Details |
PRoduction of an innOvative Millifluidic dEvice for TEsting of new prObioticsThe PROMETEO project aims to develop a millifluidic platform for studying probiotics in the gut microenvironment, enhancing drug development and clinical trial success rates. | ERC Proof of... | € 150.000 | 2023 | Details |
SmartIV
Het project onderzoekt de haalbaarheid van een bio-geïnspireerd inline infuusmonitoringsysteem om de veiligheid van IV-infusen te verbeteren door nauwkeurige flowmeting en commerciële strategieën te evalueren.
Fast and simple biomarker detection by computational microscopy
We developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics.
Development and validation of the first digital, clinical grade flow cytometry platform for enhanced diagnosis accuracy and sustainability in immunology and hemato oncology
METAflow aims to revolutionize clinical flow cytometry by providing an automated, user-friendly platform for comprehensive data analysis, enhancing usability and robustness in diagnostics.
Deep Label-Free Cell Imaging of Liquid Biopsies for Cancer Monitoring
Develop and commercialize a label-free interferometric phase microscopy device with AI for cost-effective cancer diagnosis and monitoring via liquid biopsies.
PRoduction of an innOvative Millifluidic dEvice for TEsting of new prObiotics
The PROMETEO project aims to develop a millifluidic platform for studying probiotics in the gut microenvironment, enhancing drug development and clinical trial success rates.